Posted on

Novamind Advances Clinical Pilot for Frontline KAP

Novamind Advances Clinical Pilot for Frontline KAP

nnovative treatment is a candidate to become regular service offering for healthcare workers

TORONTO, ON / February 16, 2022 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to update shareholders on a clinical pilot investigating the efficacy of group ketamine-assisted psychotherapy for frontline healthcare workers (“Frontline KAP”). With the final cohort of participants expected to begin treatment in March 2022, data analysis is currently underway and will be published following completion of the clinical pilot.

Frontline KAP represents a unique opportunity for Novamind to scale an innovative research pilot into a novel treatment program and make it accessible at all Novamind clinics. The pilot launched in July 2021, in partnership with Colorado-based Wholeness Center, to address pandemic-related stress and trauma in frontline healthcare workers. Novamind’s Chief Medical Officer, Dr. Reid Robison, and Wholeness Center’s Dr. Scott Shannon designed a six-session KAP protocol delivered in a group setting. A cohort of 40 participants are enrolled in the pilot across research sites in Utah and Colorado.

“Frontline KAP is an example of real-time, evidence-based innovation that leverages Novamind’s clinical and research expertise to bring new treatments to patient groups in need” said Yaron Conforti, CEO and Director, Novamind. “The risk of burnout in healthcare professions is strikingly high, particularly during the pandemic. We designed a protocol addressing an unmet need for healthcare workers, we’re completing the clinical pilot at our research sites, and we anticipate that Frontline KAP will be an accessible treatment available at all Novamind clinics.”

Ketamine has demonstrated efficacy for rapid relief from symptoms of depression, while the group setting provides a platform for processing trauma with peers, more effectively building community and reducing feelings of isolation compared to individual treatment. Frontline KAP involves a ratio of two therapists to four patients per cohort, greatly reducing the total number of therapist hours when compared to traditional one-on-one treatment, which increases the treatment’s affordability and enables Novamind to serve a larger patient population.

“Frontline KAP has been incredibly rewarding and meaningful for everyone involved as we’ve witnessed first-hand the healing potential of ketamine-assisted psychotherapy in a group setting that uses the power of social connection,” said Dr. Robison.

He continued, “Interim data from the pilot shows depression and anxiety scores trending down, and resilience scores going up. Many participants report having breakthroughs when assisted by the ketamine treatments, and that’s further enhanced by processing the experiences in a group setting with peers. We’re looking forward to completing the pilot and exploring the opportunity to scale access to this innovative treatment at Novamind clinics.”

To learn more about the Frontline KAP clinical pilot, please visit this link.

Posted on

Depression free for 1 year

Psychedelic therapy for depression still effective one year later

Johns Hopkins researchers followed up with patients one year after receiving psilocybin therapy. They found that 75% of patients sustained significant reductions in depression scores and 58% no longer qualified for a diagnosis. 

However, about a third of patients also used traditional antidepressants and 42% received additional psychotherapy at some point during the year.

So although psilocybin therapy can have rapid results, multiple treatment options can help sustain the benefits.

New Atlas logo

PDF of article

Posted on

AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology

AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology

CDN $3-million donation to support diversity in dermatology research, training and care

TORONTO and MONTREAL, Feb. 15, 2022 /CNW/ – AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, has made a CDN $3-million donation to establish a pioneering AbbVie Chair in Ethnodermatology at the University of Toronto’s Temerty Faculty of Medicine. One of the first positions of its kind in the world, the Chair will drive collaborative academic research, provide advanced training to the next generation of dermatological practitioners, and lead outreach programs to better inform equitable, diverse and inclusive dermatological care in Canada and around the world.

“In a field that focuses on skin, dermatology has a particular responsibility to identify and address racial inequities that influence health outcomes,” says Dr. Patricia Houston, Temerty Medicine’s Acting Dean and Vice-Dean, Medical Education. “We now recognize there are major gaps in what we know about and how we teach the approach to assessment and treatment of different skin types. The creation of the AbbVie Chair in Ethnodermatology represents a milestone philanthropic investment in our Faculty’s ongoing efforts to advance health equity, and positions U of T, AbbVie and Canada as global leaders in the emerging field of inclusive dermatology.”

Endowed chairs are maintained in perpetuity and are among the most prestigious appointments in academia. They are a powerful recruitment tool for the most talented clinicians and researchers — allowing for advancement in scholarship and research, while also showcasing a long-term commitment to a specific discipline.

Filling Gaps and Addressing Inequities
The chair’s establishment comes in response to growing calls from clinicians, researchers and patients to address longstanding gaps and inequities in dermatological research, education and patient care. In particular, there is increased recognition of the need for new investigations into the distinct impacts of skin conditions on patients of colour, for better and more in-depth data on the disparities in dermatological care provided to different populations, as well as for greater representation of skin of colour in medical education programs and curricula.

“Richly-pigmented skin is not the same in many ways — the biochemistry, biology and diseases that affect it are different,” says Dr. Marissa Joseph, assistant professor with U of T’s Temerty Faculty of Medicine and medical director of the RKS Dermatology Centre at Women’s College Hospital. “By not studying and learning the differences in presentation of disease in skin of colour, there’s an increased likelihood of misdiagnosis, treatment delays, and/or the application of inappropriate treatment approaches – all of which can have catastrophic impacts on patients. As a clinician and educator, I welcome the creation of the AbbVie Chair in Ethnodermatology and believe it can be a powerful catalyst for change.”

The need for AbbVie’s gift has also never been more relevant – nor more pressing – than it is today. According to Statistics Canada demographic projections, the proportion of Canadians who belong to a visible minority group will increase greatly by 2031. Visible minority groups could soon comprise 63% of the population of Toronto, 59% of Vancouver and 31% of Montreal1.

The inaugural chairholder will have a broad educational and research mandate. This will include leading the development of curricula to ensure future physicians and dermatologists are adequately trained to diagnose and treat skin conditions in persons of colour and to apply principles of inclusive dermatology, as well as undertaking much-needed clinical investigations into skin disorders and diseases’ distinct impact on people of colour.

Tracey Ramsay, Vice-President and General Manager of AbbVie Canada adds, “We believe it is important to ensure all Canadians have equal, fair and inclusive disease care. Equality, diversity and inclusion are among our core corporate principles and the creation of this chair is a step forward in enhancing dermatology diversity and cultural inclusion. Together with U of T, we have an opportunity to be part of a solution that will evolve the way skin care is researched, taught and practiced in Canada and hopefully across the globe.”

Dr. Christina Pelizon, Country Medical Director, AbbVie Canada adds; “We’re focused on delivering treatments in areas of high unmet medical need and as a leader in dermatology research and treatment, AbbVie is committed to the pursuit of innovation. Ultimately, this Chair will provide us a better understanding on how we can continue to make a remarkable impact on the lives of people living with serious skin diseases.”

About the Temerty Faculty of Medicine
Founded in 1843, the University of Toronto’s Temerty Faculty of Medicine consistently ranks among the top medical faculties in the world. More than a quarter of all Canadian physicians train at U of T. Together with the world-renowned hospital partners that make up the Toronto Academic Health Science Network, Temerty Medicine delivers innovative and impactful biomedical research, education and patient care that advance health and health care in Canada and beyond. For more information about Temerty Medicine, please visit temertymedicine.utoronto.ca or follow us on Twitter @uoftmedicine.

About AbbVie
AbbVie is a highly focused research-driven biopharmaceutical company that discovers and delivers innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to make a remarkable impact on people’s lives across several therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health, and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit www.abbvie.ca. Follow @abbviecanada on Twitter or find us on LinkedIn.

About AbbVie in Dermatology
For more than a decade, AbbVie has worked to uncover new solutions and improve care for people with serious skin diseases. With a broad clinical trial program, we continue to actively research and adapt to the evolving needs of the dermatology community and advance our pipeline to help people achieve their treatment goals and live beyond their skin disease.

1 “Ethnic diversity and immigration”, Canada Yearbook 2011. Statistics Canada. https://www150.statcan.gc.ca/n1/en/pub/11-402-x/2011000/pdf/ethnic-ethnique-eng.pdf?st=RK5ALCv9

SOURCE AbbVie Canada

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2022/15/c0305.html

Posted on

Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents

Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents

Vancouver, British Columbia, Canada – February 11, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”), a life sciences biotechnology company focused on research, development, and production of API grade psychedelic compounds, as well as the advancement of psychedelic assisted treatments for various mental health and neurological disorders, is pleased to announce that it has completed the acquisition (the “Transaction”) of all of the outstanding share capital of Awakened Biosciences Inc. (“Awakened”).

Awakened is a psychedelics research and technology company that has successfully developed novel technologies for the production of synthetic psilocybin, the synthetic production of psilocybin and psilocin analogues, and for the manufacturing of various no-psychoactive psilocybin-based prodrugs.  All of Awakened’s production methods have the potential to produce resultant compounds at scale, and at significantly reduced costs when compared to other production methods of the same name.

Awakened’s novel production methods have resulted in the filing of three (3) provisional patents applications with the United States Patent and Trademark Office (USPTO) for protection of these proprietary technologies.

The Transaction presents many significant and immediate benefits to the Company, including expanding the Company’s portfolio of subsidiaries specializing in the research and development of psychedelic compounds, as well as an expansion in the spectrum of methods Core One’s scientists can employ in producing psychedelic-based formulations.

Successful employment of Awakened’s patent-pending production technologies could also result in revenue generation for the Company, as some of the patent-pending methods, and resultant analogues produced, could be sold, and shipped without Controlled Drug and Substances Act (CDSA) restrictions.

The Transaction also increases the Company’s catalogue of psychedelic compounds available for clinical and medicinal research, including an array of prodrugs that would be produced from the new technologies.

Normally designed to improve bioavailability, a prodrug is described as a medication or a compound that is metabolized into a pharmacologically active drug after administration. For psychedelic compounds, prodrugs would contain the same medicinal benefits associated with psychedelics while eliminating the hallucinogenic effects.

Awakened is led by Dr. Tony Durst, an Emeritus Professor at the University of Ottawa, and renowned specialist in medicinal and natural product chemistry. Dr. Durst is a co-inventor of 14 patents applications, 14 awarded.  He is a founder of Souroubea Botanicals Inc., and a 2013 Queen Elizabeth 60th Silver Jubilee medal recipient.

The addition of Dr. Durst, along with his established relationship with the University of Ottawa, further compliments Core One’s strong scientific team led by Dr. Robert Hancock, CEO of the Company’s subsidiary Vocan Biotechnology, and establishes a relationship with another one of Canada’s leading scientific research universities, as the Company continues to build an impressive roster of leading scientific researchers.

“This acquisition is yet another illustration of Core One’s commitment to become a leading biotechnology and life sciences enterprise in the psychedelic sector. With the addition of Awakened to the Core One family, the Company has increased expansion opportunities, furthered its psychedelic products portfolio, and secured potential for immediate revenue generation. All of these factors lead toward greater market share for the Company, and to increased shareholder value,” stated Joel Shacker, Core One CEO.

Transaction Details

The Transaction was completed pursuant to a share purchase agreement among the Company, Awakened and the shareholders of Awakened (the “Definitive Agreement”) dated effective February 9, 2022.  Pursuant to the Definitive Agreement, and in consideration for the acquisition of Awakened, the Company has issued 7,030,000 common shares and 1,458,200 share purchase warrants entitling the holders to acquire an equivalent number of common shares of the Company at a price of $1.15 per share until February 4, 2024.

The Company is at arms-length from Awakened and its shareholders.  The Transaction neither constitutes a fundamental change nor a change of business for the Company, nor has it resulted in a change of control of the Company within the meaning applicable securities laws and the policies of the Canadian Securities Exchange.  In connection with completion of the Transaction, the Company has issued 140,600 common shares to certain third-parties who provided administrative services necessary to complete the Transaction.

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

Vancouver, British Columbia, Canada – February 10, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that,  further to the Company’s press release dated April 21, 2021, the Company’s team of scientists at its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has received positive results and believes that replication of its proprietary recombinant production system (the “Production System”), currently proven and utilized for the production of psilocybin, will result in successful production of API-Grade N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)).

In efforts to replicate their proprietary production system and produce DMT, Vocan scientists have uncovered this important DMT precursor NMT.  Identification of this precursor is a leading indication that production of DMT is highly probable.

With the positive identification of NMT in hand, Vocan scientists will initiate further employment of their production system to imminently produce NMT.  The sound production of NMT will lend further credence to the scientific methods currently employed, and hypothetically result in the production of DMT.

“The identification of this DMT precursor compound is a significant indication that our scientists are on the right path to producing DMT.  The successful production of NMT, which we expect to complete in the next few days, will aid in the defence of the hypothesis that our proprietary production system can be replicated to produce multiple API-grade psychedelic compounds. The successful production of DMT would widen the Company’s psychedelic products pipeline and would further establish the Company as a leading developer in the rapidly growing and competitive psychedelics industry,” stated Joel Shacker, Core One CEO.

“Core One aims to be the supplier of choice for those conducting and furthering psychedelics research.  As our scientists continually prove up the replication and viability capabilities of their production methods, I believe we are on the track to meeting this goal.”

About DMT

DMT, a naturally occurring psychedelic substance, is currently under clinical investigation for the treatment of certain mood disorders. The compound is a primary component of traditional South American entheogenic brews and is traditionally derived from the leaves of a variety of plants endemic to equatorial regions across the globe.

ABOUT CORE ONE LABS INC.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

CORE ONE LABS INC.

Joel Shacker

Chief Executive Officer

FOR FURTHER INFORMATION:

Email: info@core1labs.com

Telephone: 1-866-347-5058

FOLLOW US:

Website: https://core1labs.com/

Twitter: https://twitter.com/Coreonelabs

Facebook: https://www.facebook.com/Core-One-Labs-Inc-100969251278277/

LinkedIn: https://www.linkedin.com/company/core-one-labs

Instagram: https://www.instagram.com/coreonelabsinc/

CAUTIONARY DISCLAIMER STATEMENT

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

MINDCURE Announces Strategic Review

MINDCURE Announces Strategic Review

VANCOUVER, BC, Feb. 10, 2022 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today its Board of Directors has formed a special committee (the “Special Committee”) of independent directors to initiate a review process to explore, review and evaluate a broad range of strategic alternatives.

The Special Committee’s strategic review process will encompass an evaluation of the Company’s current strategic direction, operations, market valuation and capital structure and will consider appropriate alternatives for the Company which may include one or more of the following: continuation as a standalone public company, strategic investor investment, acquisition by or a merger with an industry partner that may involve all or part of our business or assets and any other strategic alternatives that may be identified during our strategic review.

“The Board continues to support the Company’s current strategic priorities. As we recently reported, the Company is in a strong financial position with cash and equivalents of $13.4M and a cash runway of a minimum 12 months as at November 30, 2021.  However, the Board believes that given the current state of capital markets and the evolving landscape for our industry, a broad review of strategic alternatives is entirely appropriate and in the best interest of the Company,” said the Chair of MINDCURE’s Board of Directors, Philip Tapley.

“I am proud of our team and track record of delivering on milestones with focus and drive. I look forward to engaging in this process with the Special Committee while my team pursues our ambitious plan, supported by our strong financial position,” said MINDCURE’s President and CEO Kelsey Ramsden.

The Special Committee is being chaired by Jason Pamer, includes Larissa Chaikowsky, Robert Hill and Philip Tapley, and has appointed Canaccord Genuity Corp. as its financial advisor to support the Special Committee in the strategic review process.

While the strategic review process is ongoing, the Company intends to continue to pursue its core strategic objectives so as to maintain and enhance the value of its current business and operations, including the development and launch of the iSTRYM™ product.

Other than as described in this news release, the Company has not made any decisions related to strategic alternatives at this time and there can be no assurance that the evaluation of strategic alternatives will result in any transaction proceeding or change in strategy. The Company does not intend to comment further unless and until further disclosure is appropriate or necessary.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The Company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com.

On Behalf of the Board of Directors
Jason Pamer, Chair of the Special Committee
Phone: 1-888-593-8995
Email: specialcommittee@mindcure.com

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information
Certain information regarding MINDCURE and its business presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the considerations and outcome of the strategic review; COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; no unanticipated expenses, costs or detrimental consequences of the strategic review process will arise; the continuation of the Company’s core strategic objectives, including the development and launch of the iSTRYM product, so as to preserve and enhance the value of the Company’s current business and operations; and the expected cash runway of the Company’s business.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

‍

Posted on

Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care

Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care

Vancouver, British Columbia, Canada – February 9, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that following its milestone announcement that its wholly-owned subsidiary, Vocan Biotechnologies Inc. (Vocan), has successfully engineered a novel recombinant production system for biologically synthesized (biosynthesized) psilocybin, and has filed for patent protection of its groundbreaking intellectual property (see Core One’s press release dated January 21, 2022), its team of scientist continue to make progress and are in the process of optimizing at scale production capacity.

Scaled up production of the Company’s groundbreaking biosynthetic psilocybin, and an approval of the Company’s patent application will further Core One and Vocan’s journey to becoming a significant player in the provision of cost effective psilocybin and has the potential to significantly change the face of psychedelic-based mental health care and patient access to alternative treatments around the globe.

Psilocybin is a psychedelic compound that is showing enormous promise in treating addiction and many mental health disorders; and the success of this game-changing patent propels Core One to the forefront of the rapidly expanding psychedelics industry, eliminating barriers for psychedelic treatments and research such as exorbitant costs and lack of availability and supply.

Currently, most companies use chemically synthesized psilocybin as the only available cGMP compliant product that is available in large volumes. The chemical process carries significant costs and is less efficient when compared to a biologically derived psilocybin.

Under the leadership of Dr. Jan Burian, Vocan’s Chief Scientist, and Dr. Robert EW Hancock, Vocan’s CEO, the team’s ground-breaking psilocybin production method utilizes the well-established industrial process of fermentation and therefore can be scaled up while consistently producing a high-quality cGMP product. The process turns bacteria into a biological factory to produce synthesized psilocybin, cutting cost and time immensely.

With Vocan’s optimized recombinant production system, the subsidiary successfully tested its proof-of-concept for the manufacturing of biosynthetic psilocybin suitable for use in future scale-up and is awaiting patent approval. The application includes claims that Vocan’s technology will enable the production of cGMP API grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials and, where permitted by law, consumers, and patients. Vocan’s crucial breakthrough anticipates a rippling effect that could rearrange the industry’s landscape hereafter.

“This breakthrough in psilocybin production, can shift the entire industry. By making psychedelic treatments cost effective, this could make treatment more widely available to patients globally. Additionally, our patent on this process, gives us first mover advantage in this significant and emerging space,” Stated Joel Shacker CEO of the Company.

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

Ehave Issues Shareholder Letter and Provides Corporate Update

Ehave Issues Shareholder Letter and Provides Corporate Update

MIAMI, Jan. 31, 2022 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan.

Dear Fellow Shareholders,

Ehave is focused on progressing Psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health led by technology. We have built a network of like-minded scientists and mental health professionals combined with technology, who share our mission to create safe and effective therapeutics by leveraging clinical data to help us address mental health issues to achieve optimal patient outcomes.

Why Ehave is Important In The Psychedelic Ecosystem

Before I discuss the upward inflection points Ehave achieved in 2021, I would like to provide a reminder of the problem we are targeting and our mission to impact it. At its core, the problem is simple – In America, 21% of U.S. adults experienced mental illness in 2020 (52.9 million people), 5.6% of U.S. adults experienced serious mental illness in 2020 (14.2 million people), 16.5% of U.S. youth aged 6-17 experienced a mental health disorder in 2016, 6.7% of U.S. adults experienced a co-occurring substance use disorder and mental illness in 2020, and suicide is the 2nd leading cause of death among people aged 10-34. We are confident in our ability to deliver solutions because we have built a team that understands the challenges facing mental health.

Reflecting on 2021, I am very grateful for the accomplishments and progress we have made. As much of the heavy lifting has been completed, I am more positive than ever on both Ehave and the opportunities that lie ahead. Last year was a foundational year that set the stage for Ehave by developing breakthrough products and assembling a talented and expert team to execute our strategy for the future. As we move forward in 2022, we find ourselves strategically positioned with a strengthened balance sheet, a deep bench of experienced industry professionals, an exceptional portfolio of products and services, and an opportunity to provide an increased quality of mental health through data based psychedelic medicine. With a great deal of the development accomplished, we plan to engage with what I believe will be yet another transformative year for the company as we move towards monetizing Ehave’s investments by licensing our technology to other enterprises in an effort to advance research and commercialization of psychedelics.

Mycotopia Therapies

On December 28, 2020 Ehave sold 100% of its Mycotopia Therapies (OTC: TPIA) subsidiary to 20/20 Global Inc. for $350,000 and 75.77% of 20/20 Global’s outstanding shares in order to maximize Mycotopia Therapies value for our shareholders. The company was subsequently renamed Mycotopia Therapies and is traded on OTC Markets under the symbol TPIA. Less than a year later, Mycotopia Therapies announced it had signed an LOI to explore a merger with Ei.Ventures that will form PSLY.COM in a $360 million transaction that includes applying to list the new company’s shares on NASDAQ. Fulfilling our promise to maximize Mycotopia Therapies value for our shareholders, Ehave announced plans to spin out 30% of its PSLY.COM holdings to Ehave shareholders on a pro-rata basis. We anticipate this happening in the first half of 2022.

Ei.Ventures’ flagship botanical psilocybin-based formulation Psilly is a whole-plant botanical psilocybin-based formulation, which is currently in the pre-clinical phase. The goal of the combined companies would be to complete pre-clinical and phase 1 trials and launch therapeutic Psilly into jurisdictions where psilocybin is legal. Ei.Ventures recently announced the acquisition of a 12×12 estate in The Sandbox, a virtual world where players can build, own, and monetize their gaming experiences on the Ethereum blockchain, which represents the third-largest land sale in the Metaverse valued at $2.22M. The land will be called PSLY.COM, the name of the soon-to-be merged company of Ei.Ventures with Mycotopia Therapies.

KetaDASH Home Delivery Service

Early in 2021, Ehave announced plans for KetaDASH, a platform for medical practitioners to administer ketamine intravenously to patients at home. KetaDASH has evolved into a managed service organization focused on the psychedelic sector, with the ability to help doctors increase both patients and the revenue, as well as expand and manage their practice. Widely used for pain after certain medical procedures, Ketamine is now being studied as a treatment for major depression, though it has not yet been approved by the FDA to treat depression. We believe Ketamine has rapid antidepressant properties in unipolar and bipolar depression. An antidepressant effect has been reported as soon as 40 minutes after ketamine infusions, which is why we are rolling out our ketamine home delivery platform. The backbone for KetaDASH will be Ehave’s expertise in the area of digital therapeutics, which has been developed through years of testing in the area of mental healthcare. Ehave’s digital therapeutics insight will empower patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

After years of continued work to develop its proprietary digital therapeutics technology, Ehave is ahead of other psychedelic companies that are in the process of building integrated technical platforms and comprehensive toolsets to deliver psychedelic inspired medicines and experiential therapies combined with digital therapeutics. Ehave also plans to launch brain mapping ketamine clinical trials using Brain Scientific technology in Miami with Tristar Wellness. The clinical trial, originally planned for year-end 2021, but delayed by Covid, will establish the statistical correlation between the ketamine treatment and patient improvement from the disorders. We plan to utilize an Institutional Review Board, which will review all research involving human subjects and implement policies and procedures regarding such research.

KetaDASH offers Ehave shareholders our fastest path to becoming a revenue generating company. KetaDASH offers ketamine for treatment resistant depression, anxiety, PTSD, and other conditions. After a short telemedicine visit, an experienced nurse will arrive at your location of choice to administer the sublingual treatment. Ehave plans to start its KetaDASH service this month in the San Francisco and Sacramento California area. Through our agreement with the telemedicine platform getheally.com, KetaDASH will have access to doctors in all 48 continental states. This will allow us to scale KetaDASH and expand it quickly. It is important to note Ehave and KetaDASH comply with all federal regulations. In an effort to continue to be compliant, our business plan calls for pairing each patient with a nurse to administer the treatment. I would like to invite you to learn more about the products and services offered by KetaDASH at www.ketadash.com.

MegaTeam

Ehave’s MegaTeam assessment and rehabilitation products are built on established methodologies for the measurement of cognitive abilities in populations with attention deficit hyperactivity disorder (“ADHD”). The MegaTeam products embed cognitive assessment and rehabilitation tasks within an engaging video game environment. iOS/Android Versions are currently being added to play stores. Ehave’s Ninja Reflex is a video game intervention for kids with neurodevelopmental disorders.

Ehave has conducted two Clinical Trials at the Hospital for Sick Children in Toronto for its MegaTeam-videogame as an intervention/treatment for ADHD. One has been closed and the second is ongoing.

Our initial trial started in September, 2016 and ended in April, 2017 with a pilot study of 35 participants. The trial showed the longer you practice on the game, the better your ability to stop a speeded motor response is, and the better you get at manipulating information in short-term working memory. https://clinicaltrials.gov/ct2/show/NCT02827188.

Our second trial started April, 2018 and is ongoing under supervision of Dr. Jennifer Crosbie with over 100 patients recruited to date. The Clinical Trial was sponsored by The Hospital for Sick Children in Ontario, Canada and was titled Cognitive Restructuring in ADHD: Functional Training (CRAFT) study. The objective of the study was to develop a non-pharmacological intervention program for children with ADHD. The Canadian government invested over $1,000,000.00 in grants in this closed study. Investors can find more information on our Clinical Trial on the U.S. National Library of Medicine’s Clinical Trials website at https://clinicaltrials.gov/ct2/show/NCT03502239.

HPPD Study with University of Melbourne

In 2021 our research took us to the other side of the world as we announced a partnership with the University of Melbourne to gather data and bio-markers to target Hallucinogen Persisting Perception Disorder (“HPPD”). We look forward to continuing this partnership into 2022 and will look to create bio lines and a testing revenue model as well as screening products capable of indicating HPPD. Hallucinogen-persisting perception disorder, or HPPD, can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. Ehave believes the key to widespread acceptance for psychedelics is a focus on the good as well as the bad, which is why we are investing in this series of studies on HPPD.

Currently, researchers at the University of Melbourne have completed the necessary documents required for university ethics approval for online study of HPPD, and are updating the ethics documents for re-submission before the pilot can take place This includes recruitment, plain language statement, consent form, and debriefing. The researchers have also submitted a full ethics application, and are awaiting a decision on minimal risk accreditation. They have received preliminary approval for the pilot project to be considered “low or negligible risk,” and received ethics board review feedback on the submission seeking clarification on the role of funders regarding data, as well as minor clarifications on surveys/tasks being used.

MetaHealthU

With the growing popularity of the Metaverse, we believe 2022 will be a great year for our MetaHealthU, a mobile application platform that empowers individuals to take complete control of their health and their healthcare data. With Meta HealthU, users can securely track all their health data from wearables, Electronic Health Records Systems (EHRs), Doctors and Medical Labs. The app is available for iOS 11.0 or later, Android, and includes a “digital file cabinet” for medical records. Features include easy to use navigation and search capabilities for users to collect, file and tag their medical records on their mobile device. Users can log into their patient portals on various healthcare systems and medical labs and download their medical records in the digital file cabinet.

The social connectivity aspects of this version of the app usher in a new era of digital health where users create and become part of their ‘social health network’. Meta HealthU users can create their own health-oriented Campaigns and Challenges and invite their friends, family and colleagues to participate in these Campaigns and Challenges. Combining the social aspects of health with the ability for users to create their own health-related challenges and campaigns provides powerful incentives to be and to stay healthy. For example, users can chip in a participation fee in the form of OmPoints to a “Challenge Purse” and compete to win OmPoints from the purse. The digital wallet connectivity with the blockchain enables users to bundle and share their health records in a secure and seamless way while earning OmPoints. The digital wallet stores reward points users can accumulate by participating in health-related Campaigns and Challenges. Institutions, such as Hospitals and Pharmaceutical companies, can fund health-related campaigns or research, create cohorts and invite them to participate. Using the Campaign Wizz Bridge Application Dashboard, they can reward participants with OmPoints for taking part in clinical trials or for adopting a healthy lifestyle. Users will be able to redeem OmPoints they have accumulated over time for Amazon Gift Cards or other gift cards which they can use for purchases.

Our health wallet is based on MyEtherWallet which will in the future allow users to mint their health records as an NFT. The function of having an immutable record of ownership or agreement minted onto a blockchain has such rich potential to impact so many industries. The most exciting use cases beyond the current iteration of NFTs include medical records, clinical trial results, and retreat results.

Ehave Dashboard Is Now Part Of MetaHealthU

The Ehave Dashboard is our flagship product. Over the years it has evolved into a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. Through our technology we offer Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

Ehave has developed a medical record exchange plugin that will allow patients to own their own healthcare records and work more closely with medical professionals and psychedelic researchers to target conditions that are poorly addressed by the healthcare system today, such as chronic diseases, treatment-resistant depression, and neurological disorders. Plans for 2022 include monetizing this asset. Ehave also formed a partnership for our Dashboard with Health Wizz, a Digital Healthcare IT venture focused on FHIR interoperability and employee wellness, and BurstIQ, the leading provider of blockchain-based data solutions for the healthcare industry. Ehave will use BurstIQ’s privacy-protecting technology to link clinical trial data using its Dashboard and AI to health data from various sources, including wearables, lab reports, and doctor and hospital visits. Ehave allows us to provide our Dashboard users an opportunity to manage their personal medical records and retrieve them through a dedicated instance on the AWS (Amazon Web Services) platform.

Also in 2022, Ehave plans to monetize the AI technology it licensed from Vastmindz to expand the Ehave Dashboard and Ehave Medical App offerings. The AI technology will provide the Ehave Dashboard and Ehave Medical App with the ability to identify an individual’s physiological condition, such as Heart Rate, Heart Rate Variability (HRV), Respiration Rate, Oxygen Saturation Level, and other vital statistics. These changes in physiological condition will be identified by extracting information about changes in light absorption on an individual’s facial skin. No different than taking a selfie, the changes are captured within the RGB pixel values of camera frames and converted into various physiological vitals utilizing Vastmindz proprietary AI.

In Closing

Also in 2021, Ehave appointed Jeffrey D. Kamlet, MD, FASAM, DABAM to the position of Chief Medical Officer. Dr. Kamlet brings more than 30 years of Internal Medicine, Addiction Medicine and Pain Management experience to Ehave. He has also served as a Principal Investigator on over 20 major pharmaceutical clinical trials.

Moving forward we will continue to pursue a listing on a Canadian Stock Exchange and uplisting to the OTCQB Exchange, both of which were delayed in 2021 due to Covid. We will also continue to pursue closing the acquisition of 100% of Moksha Digital Software Pvt. Ltd., a provider of medical imaging software and the creator of the FDA cleared CuriePACS and CurieRIS solutions.

Our diverse team is our strength. As a result, we actively promote diversity and inclusion in all our projects by ensuring minority, women-owned, and small business participation in our industry. In 2021, we announced our firm commitment to sustainability and corporate responsibility, and we believe non-financial factors, such as environmental, social, and governance are a major part of identifying material risks and growth opportunities.

We look forward to sharing our accomplishments in the coming year as we strive to create value for our customers, shareholders, and employees – and we thank all our stakeholders for their support of our mission.

Sincerely,

Ben Kaplan
Chief Executive Officer

About Ehave, Inc.

Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

For Investor Relations, please contact:

David Kugelman
(866) 692-6847
(404) 281-8556 Mobile and WhatsApp
Skype: kugsusa
ir@ehave.com

Posted on

MDMA Passport + Commercial LSD Study: issue 34

Hello and welcome back.

Who else is counting down the days til the Daily Mushroom + Entheon Biomedical Mental Health Town Hall?? If you haven’t registered yet, you can do so here. What are you waiting for? It’s totally free and virtual so anyone can attend.

Here’s what’s in store for you in today’s issue:

🍄 The psychedelic that’s already in our brains

🍄 MAPS receives Innovation Passport for MDMA therapy 🎉

🍄 First commercial study of LSD in 40 years

🍄 Will Oregon legalize microdosing?

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

7 days of tripping to heal mentally, physically and radically change a career path

In this episode of The Daily Mushroom Podcast, we have Cory Firth, Executive Director of The Canadian Psychedelic Association and founder of DoseDay! Cory opens about his battle with mental health and shares his experience with psychedelics in his quest to find meaning in his life. He also talks about how he got himself into a 7 ayahuasca retreat and what that journey gave him.

Therapeutic banner

First commercial study of LSD in 40 years

MindMed’s LSD-based compound received FDA clearance, allowing the company to proceed with a trial that will be the first commercial study of LSD in over 40 years.

The study will assess 200 patients with generalized anxiety disorder to find the optimal dose of the formulation. 

Shares of MNMD spiked 30% following the announcement 💰

Goodbye Blue Mondays

A recent study found pure MDMA administered in a clinic does not have the “come down” effect that recreational users often report the day after dosing. 

Participants maintained a positive mood during the week following the dose. Plus, no participant had used or desired to use illegal MDMA at the 3 month and 6 month follow ups.

Mario’s secret revealed 🍄

The iconic red and white spotted mushroom (officially called Amanita Muscaria and unofficially called the Super Mario mushroom) is showing potential to treat arthritis.

Psyched Wellness (PSYC) is working with the National Research Council of Canada (NRC) to study the mushroom’s properties. It doesn’t contain psilocybin, but has a different psychoactive component called muscimol.

Preliminary data suggests that Amantia Muscaria could reduce inflammation in the skin, gut, brain, and lungs. The company believes it has potential to treat chronic inflammatory conditions like arthritis.

Maybe that’s why Mario can jump so high without destroying his joints 😉

inspirational banner

MAPS receives Innovation Passport for MDMA therapy 🎉

The Innovation Passport will make MDMA therapy for PTSD widely available in the UK, as rapidly as possible!

The Multidisciplinary Association for Psychedelic Studies (MAPS) found that 88% of patients had a reduction in PTSD symptoms after three MDMA sessions in conjunction with trauma-focused therapy. 

The organization was granted an Innovation Passport for the treatment – a UK designation that speeds up the timeline for approval of innovative medicines for life-threatening conditions (similar to Breakthrough Therapy Designations in the US, which the treatment received in 2017).

The psychedelic that’s already in our brains

Did you know that one of the most promising addiction treatments is a psychedelic compound that’s found throughout nature and is present within the human body?

It’s called DMT (N,N-Dimethyltryptamine) and is thought to be produced in the brain’s pineal gland. DMT is released in large amounts when we dream and when we die.  

Learn what leading DMT experts have discovered at the Daily Mushroom + Entheon Biomedical Mental Health Town Hall on Thursday, Feb. 3rd. Register now for free to get the inside scoop 👇

Donating psilocybin to patients in need

CCrest Laboratories is donating psilocybin truffles so patients in need can access the medicine for free through Canada’s Special Access Program (SAP).

The company was just approved as a licensed psilocybin producer by Health Canada, along with Numinus Wellness (NUMI) and Filament Health’s (FH) Psilo Scientific, allowing them to supply psilocybin for clinical trials and emergency treatments through the SAP. 

The truffles will be grown by Red Light Holland (TRUFF) and tested at CCrest Labs before being donated as part of their “compassionate need and free supply” approach.

business banner

Beckley Psytech began training psychotherapists for a phase II study on 5-MeO-DMT for treatment-resistant depression through Fluence’s interactive training program. Within the next year, Beckley aims to train 80 psychotherapists on how to administer psychedelic therapy.

Mydecine (MYCO) is partnering with a UK-based charity called Combat Stress and the King’s College London to study psilocybin therapy as a treatment for veterans with severe, treatment-resistant PTSD. 

Psygen Labs entered into an agreement to supply Universal Ibogaine (IBO) with ibogaine for an upcoming clinical trial on opioid addiction.

atai Life Sciences (ATAI) launched a wholly owned platform company called Invyxis, which will focus on developing novel compounds that target serotonin 5-HT2A receptors.

Akome Biotech, a subsidiary of Core One Labs’ (COOL), signed a consulting agreement with the University of Barcelona to develop psychedelic treatments for depression, stroke, Parkinson’s, and Alzheimer’s.

Ketamine One (MEDI) changed its name to Wellbeing Digital Sciences and partnered with Nova Mentis (NM) to study psilocybin microdosing for fragile x syndrome.

legal banner

Oregon is on track to provide legal psilocybin services in 2023

But one question remains unanswered: will the new program include microdosing?

For the past year, the Oregon Health Authority has been planning the regulatory framework to implement Measure 109, which legalized psilocybin sessions under the care of licensed facilitators. The program is on schedule to roll out at the beginning of 2023.

At the latest public Zoom meeting, a push to include microdosing in the program received backlash from some advisory board members, but others thought it was worth considering. Members have until the end of June to reach a consensus.

 

Two psilocybin bills filed in Oklahoma

The first bill would promote research focused on treating depression and anxiety in veterans. The second would promote research into 10 different conditions and reduce the penalty for psilocybin possession to a fine.

Video of the Week

The Battle Over Psychedelic Therapy’s Future

Playlist of the Week

Trippy Songs 🍄🍃👽🚀
Posted on

Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences

Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences

Vancouver, British Columbia, Canada – January 26, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has signed a consulting agreement with the Universitat de Barcelona (the “University of Barcelona” or the “University”), Faculty of Pharmacy and Food Sciences, Laboratory of Medicinal Chemistry, of Barcelona, Spain.

By virtue of this agreement, Professor Maria Carmen Escolano, a full professor at the University’s Unit of Medicinal Chemistry in the Faculty of Pharmacy and Food Sciences, and her team will provide technical guidance for the in vitro development of Akome’s psychedelic based bioactive compounds targeting Major Depressive Order, Stroke, Parkinson’s Disease and Alzheimer’s Disease.

The University of Barcelona, Faculty of Pharmacy and Food Sciences, Laboratory of Medicinal Chemistry, has been selected by Akome as the successful candidate organization to provide technical guidance for the necessary in vitro studies of its proposed pharmaceutical psychedelic drug formulations.

Conducting in vitro studies is essential in the development of any new pharmaceutical drug. In vitro studies determine whether a pharmaceutical candidate produces the desired changes on cell cultures as an early indicator of efficacy. These studies are usually completed quickly and are designed based on information already presented in the provisional patents that have been filed by Akome.

Professor Escolano received her PhD from the University of Barcelona in 1993. Upon completion, she undertook research posts at the University College of London and Kingston University (UK) working in the synthesis of complex molecules with biological interest. Professor Escolano currently serves as a full professor at the Unit of Medicinal Chemistry in the Faculty of Pharmacy and Food Sciences, a post she has occupied for the last 14 years.

Professor Escolano leads the medicinal research group at the Universitat de Barcelona. The focus of this research group is the pharmacology of neurodegenerative diseases. Professor Escolano and her group have conducted in vitro development of multiple candidate substances for the treatment of neurological conditions. Professor Escolano is a renowned authority in the field, with over 95 publications in textbooks and peer-reviewed scientific journals. Akome is looking forward to the advancement of its pipeline of bioactive compounds specifically those targeting the neurodegenerative diseases, Parkinson’s and Alzheimer’s.

“We are excited to announce our contract with the University of Barcelona, Faculty of Pharmacy and Food Sciences, Laboratory of Medicinal Chemistry,” stated Joel Shacker CEO of the Company.  “Professor Escolano and her team have an enormous amount of experience, and knowledge of the targeted diseases, and the research acumen that will allow Core One to efficiently move forward with the more in-depth in vitro and in vivo studies that are necessary in effectively mapping out development of pre-clinical trials.”

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.